Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1983 Oct;80(19):6086–6090. doi: 10.1073/pnas.80.19.6086

Inhibition of thromboxane A2 synthesis in human platelets by coagulation factor Xa.

A K Sinha, A K Rao, J Willis, R W Colman
PMCID: PMC534365  PMID: 6577468

Abstract

Factor Xa binds to platelets provided that factor Va is present on the platelet surface, an interaction that results in a striking acceleration of the conversion of prothrombin to thrombin. Thrombin then initiates fibrin formation, induces platelet aggregation, and stimulates the intraplatelet synthesis of thromboxane A2 (TXA2). Addition of thrombin (2.4-14.4 nM) to platelet-rich plasma increased the basal level of TXA2, measured as thromboxane B2, from less than 0.5 pmol per 10(8) platelets to (mean +/- SEM) 100 +/- 22 and 250 +/- 10 pmol per 10(8) platelets, respectively. Treatment of platelet-rich plasma with increasing concentrations of factor Xa (1-12 nM) prior to the addition of thrombin progressively inhibited the production of TXA2. Thrombin (9.6 nM), which produced 93% of the maximal formation of TXA2, was inhibited 70% by factor Xa (10 nM). To identify which of these steps in thromboxane synthesis was inhibited by factor Xa, platelets labeled with [14C]arachidonic acid were exposed to thrombin and products of prostaglandin synthesis were separated by thin-layer chromatography. In contrast to the inhibition of TXA2 synthesis, prostaglandin E2 and prostaglandin F2 alpha synthesis were not inhibited suggesting that neither phospholipase(s) nor cycloxygenase was involved. The inhibition of TXA2 formation by factor Xa could be reversed by increasing the molar ratio of thrombin to factor Xa to 5.5. Incubation of platelets with an IgG fraction of a human monoclonal antifactor V antibody, previously shown to inhibit factor Xa binding, was found to block factor Xa inhibition of TXA2 synthesis. The inhibition of TXA2 synthesis requires the presence of the active site serine of factor Xa and is not specific for TXA2 formation induced by thrombin because it is also demonstrable when the agonist is ADP. Further, factor Xa does not require additional plasma components for its action because its inhibitory effects are detected in gel-filtered platelets. The effect of factor Xa was evident at physiological (1.3 mM) calcium concentrations. These results indicate that factor Xa binding to platelets through factor Va not only stimulates thrombin formation but also has a countervailing effect by inhibiting TXA2 formation.

Full text

PDF
6086

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bajaj S. P., Mann K. G. Simultaneous purification of bovine prothrombin and factor X. Activation of prothrombin by trypsin-activated factor X. J Biol Chem. 1973 Nov 25;248(22):7729–7741. [PubMed] [Google Scholar]
  2. COLE E. R., MARCINIAK E., SEEGERS W. H. Procedures for the quantitative determination of autoprothrombin C. Thromb Diath Haemorrh. 1962 Dec 20;8:434–441. [PubMed] [Google Scholar]
  3. Chesney C. M., Pifer D., Colman R. W. Subcellular localization and secretion of factor V from human platelets. Proc Natl Acad Sci U S A. 1981 Aug;78(8):5180–5184. doi: 10.1073/pnas.78.8.5180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Di Scipio R. G., Hermodson M. A., Yates S. G., Davie E. W. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry. 1977 Feb 22;16(4):698–706. doi: 10.1021/bi00623a022. [DOI] [PubMed] [Google Scholar]
  5. Fenton J. W., 2nd, Fasco M. J., Stackrow A. B. Human thrombins. Production, evaluation, and properties of alpha-thrombin. J Biol Chem. 1977 Jun 10;252(11):3587–3598. [PubMed] [Google Scholar]
  6. Greenquist A. C., Colman R. W. Bovine factor v: a calcium-containing metalloprotein. Blood. 1975 Nov;46(5):769–782. [PubMed] [Google Scholar]
  7. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hurtubise P. E., Coots M. C., Jacob D. J., Muhleman A. F., Glueck H. I. A monoclonal IgG4 (lambda) with factor V inhibitory activity. J Immunol. 1979 May;122(5):2119–2121. [PubMed] [Google Scholar]
  9. Jesty J., Esnouf M. P. The preparation of activated factor X and its action on prothrombin. Biochem J. 1973 Apr;131(4):791–799. doi: 10.1042/bj1310791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jesty J., Spencer A. K., Nemerson Y. The mechanism of activation of factor X. Kinetic control of alternative pathways leading to the formation of activated factor X. J Biol Chem. 1974 Sep 10;249(17):5614–5622. [PubMed] [Google Scholar]
  11. LEWIS M. L., WARE A. G. A one-stage method for the determination of accelerator globulin. Proc Soc Exp Biol Med. 1953 Dec;84(3):640–643. doi: 10.3181/00379727-84-20738. [DOI] [PubMed] [Google Scholar]
  12. Lages B., Scrutton M. C., Holmsen H. Studies on gel-filtered human platelets: isolation and characterization in a medium containing no added Ca2+, Mg2+, or K+. J Lab Clin Med. 1975 May;85(5):811–825. [PubMed] [Google Scholar]
  13. Leveson J. E., Esnouf M. P. The inhibition of activated Factor X with di: isopropyl fluorophosphate. Br J Haematol. 1969 Aug;17(2):173–178. doi: 10.1111/j.1365-2141.1969.tb01356.x. [DOI] [PubMed] [Google Scholar]
  14. Lewy R. I., Smith J. B., Silver M. J., Saia J., Walinsky P., Wiener L. Detection of thromboxane B2 in peripheral blood of patients with Prinzmetal's angina. Prostaglandins Med. 1979 Apr;2(4):243–248. doi: 10.1016/0161-4630(79)90059-4. [DOI] [PubMed] [Google Scholar]
  15. Marcus A. J. The role of lipids in platelet function: with particular reference to the arachidonic acid pathway. J Lipid Res. 1978 Sep;19(7):793–826. [PubMed] [Google Scholar]
  16. Miletich J. P., Jackson C. M., Majerus P. W. Interaction of coagulation factor Xa with human platelets. Proc Natl Acad Sci U S A. 1977 Sep;74(9):4033–4036. doi: 10.1073/pnas.74.9.4033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Miletich J. P., Jackson C. M., Majerus P. W. Properties of the factor Xa binding site on human platelets. J Biol Chem. 1978 Oct 10;253(19):6908–6916. [PubMed] [Google Scholar]
  18. Moncada S., Vane J. R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 1978 Sep;30(3):293–331. [PubMed] [Google Scholar]
  19. Nugteren D. H., Hazelhof E. Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim Biophys Acta. 1973 Dec 20;326(3):448–461. doi: 10.1016/0005-2760(73)90145-8. [DOI] [PubMed] [Google Scholar]
  20. Sinha A. K., Shattil S. J., Colman R. W. Cyclic AMP metabolism in cholesterol-rich platelets. J Biol Chem. 1977 May 25;252(10):3310–3314. [PubMed] [Google Scholar]
  21. Tracy P. B., Peterson J. M., Nesheim M. E., McDuffie F. C., Mann K. G. Interaction of coagulation factor V and factor Va with platelets. J Biol Chem. 1979 Oct 25;254(20):10354–10361. [PubMed] [Google Scholar]
  22. Walsh P. N., Pareti F. I., Corbett J. J. Platelet coagulant activities and serum lipids in transient cerebral ischemia. N Engl J Med. 1976 Oct 14;295(16):854–858. doi: 10.1056/NEJM197610142951602. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES